Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

The three-signal paradigm tries to capture how the innate immune system instructs adaptive immune responses in three well-defined actions: (1) presentation of antigenic peptides in the context of MHC ...

THE RELATIONSHIP between biologic therapies and the risk of major adverse cardiovascular events (MACEs) and venous ...

Teaser: Off-label systemic agents may treat inflammatory autoimmune vulvar diseases such as lichen sclerosus and lichen ...

Professor Martin Röcken discusses challenges and opportunities in dermatology care, immunotherapy, the MDT and his hopes for ...

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...